Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: A matched case analysis Journal Article

   

Authors:	Moss, N. S.; Singh, J. M.; Reiner, A. S.; Drago, J. Z.; Modi, S.; Seidman, A. D.; Chandarlapaty, S.; Ross, D. S.
Article Title:	Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: A matched case analysis
Abstract:	The HER2-directed antibody-drug conjugate trastuzumab deruxtecan is active against lower levels of HER2 expression than prior-generation therapies. The rate of HER2 expression in brain metastases among patients with initially HER2-null breast cancer is undefined, and receptor discordance in advanced breast cancer with brain metastases may underestimate CNS response potential in the absence of brain metastasis sampling. In this cohort study including 136 patients with 401 samples scored according to ASCO/CAP guidelines, 15/28 patients (54%) with HER2-null primary breast cancer have detectable HER2 expression in subsequently resected brain metastases, a significant discordant population. © 2023, Springer Nature Limited.
Journal Title:	npj Breast Cancer
Volume:	9
ISSN:	2374-4677
Publisher:	Nature Publishing Group
Date Published:	2023-10-23
Start Page:	86
Language:	English
DOI:	10.1038/s41523-023-00592-5
PROVIDER:	scopus
PMCID:	PMC10590773
PUBMED:	37867174
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85174577584&doi=10.1038%2fs41523-023-00592-5&partnerID=40&md5=b7d3c997276c4d16e434b499bf344290
Notes:	Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PDF -- MSK corresponding author is Nelson Moss -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/210595